@JustAnotherPM Sid, finding the right problem to solve is an incredible driver. The “right” varies by an individual, but once you find it - you’d find ways to evolve to tackle even draining leaders.
@JustAnotherPM This is good Sid
Starting the lifecycle with right vision is critical. I’d change the question from “where to go” to “why are we building” to capture the potential impact of the effort upfront.
Today is a special day for @whatifventures and @AltoNeuro. Alto completed their #IPO on the NYSE under the ticker "ANRO." 🚀
I started What If Ventures for the purpose of funding Mental Health solutions that could help people like me. This investment in Alto Neuroscience really epitomizes what we are all about and why we exist.
Alto is redefining mental health and #psychiatry by making precision medicine a reality in the mental health space. The Company has 4 lead drug candidates in clinical trials today focused on treating #Depression, #PTSD, #Schizophrenia, and #Bipolar Depression.
I am also particularly proud of this investment because of our history with the Company. I met the founder, @AmitEtkin in February 2020 and spent over a year begging him to let me invest in Alto Neuroscience. I set a calendar reminder to email him every month for nearly a year and a half. Finally, he decided it was time to take on venture money and I introduced him to the firm that led the Series-A.
What If Ventures wrote our biggest check to date into that April 2021 Series-A round (a check that almost eclipsed our entire investing amount from the prior calendar year).
Then in 2022, we followed on in the Series-B, when the biotech market was crashing and nobody wanted anything to do with private company biotech investing. Finally, in November 2023, we followed on again in the Series-C (crossover round with Point72, @EliLillyandCo, @FTI_US, and others) making Alto Neuroscience one of our most significant holdings.
So, it's a bit of an understatement to say that we're excited. 😁
If you're not familiar with Alto Neuroscience, the company is a clinical-stage biopharmaceutical company on a mission to redefine #psychiatry by leveraging #neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of research by founder, Dr. Amit Etkin, Alto aims to deeply understand brain function and match patients to the right medication more efficiently using treatments that, if approved, are tailored to specific patient populations.
As a result, Alto believes they can help patients avoid the often lengthy process of trying multiple ineffective treatments before finding one to which they respond, potentially helping patients get better faster. This is truly giving hope to people who have never had a real solution. This company will absolutely drive lasting change in how we treat mental health indications.
For that, I'm grateful personally and professionally to Amit Etkin, Nick Smith and team. Thank you guys for letting me and our LPs be along for this ride with you!
@aakashgupta Project management is a huge part of being a PM. The variance of focus on spectrum of Project to Product is not only role or personality, but also cultural specific.
Tech startup Humane has dropped its first consumer device...and it's really cool
Called the Ai Pin, it's integrated with ChatGPT and projects information onto the users palm
Could you see this replacing your smartphone?